| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 86.8MM | +6% |
| Gross Profit | 73MM | +9% |
| Cost Of Revenue | 13.8MM | -6% |
| Operating Income | 26.9MM | - |
| Operating Expenses | 46.1MM | - |
| Net Income | 53.5MM | - |
| R&D | -5.5MM | -273% |
| G&A | 54.3MM | +3% |
| Amortization | 191K | +1% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT Since the report of 2023 full year results on February 28th, MiMedx Group, Inc. (NASDAQ:MDXG) has received an update on its request for designation for Axiofill from the FDA. It has also signed a commercialization agreement with TELA Bio to distribute xenograft products, introduced an e-commerce and account management
Receives Determination Letter from FDA Stating AXIOFILL Does Not Qualify for Classification as an HCT/P Under Section 361 MIMEDX Continues to Pursue All Available Options to Keep AXIOFILL on the Market Reiterates Expectations for 2024 Net Sales Percentage Growth in the Low Double Digits and 2024 Adjusted EBITDA1 Margin Above 20% MARIETTA, Ga., March 27, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that the U.S. Food and Drug Administratio
Unless you borrow money to invest, the potential losses are limited. But if you pick the right stock, you can make a...
Exclusive agreement provides MIMEDX with rights to commercialize 510(k) cleared, bovine-derived collagen matrix particulate that is indicated for the management of exudating woundsMARIETTA, Ga., March 20, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has entered into an agreement with TELA Bio, Inc. to obtain exclusive rights to its manufacturing and supply agreement with Regenity Biosciences that will enable the Company to add xen
Designed to Streamline Ordering, Payment Processing, and Reimbursement SubmissionsMARIETTA, Ga., March 13, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the launch of MIMEDX Connect™, an online product ordering and account management portal available to its customers through the Company’s website. “In our ongoing commitment to improve our customers’ experience, we are excited to introduce the MIMEDX Connect platform, which is designed to s
MARIETTA, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as of March 1, 2024. Ms. Olson and Ms. Puhy each bring extensive and relevant experience across the healthcare industry, with demonstrated records of executive leadership, strategic counsel and shareholder value creation. In connection with these appointments, the Board of Directors
MiMedx Group (NASDAQ:MDXG) has had a great run on the share market with its stock up by a significant 5.4% over the...
MiMedx Group ( NASDAQ:MDXG ) Full Year 2023 Results Key Financial Results Revenue: US$321.5m (up 20% from FY 2022). Net...
MiMedx Group, Inc. (NASDAQ:MDXG) Q4 2023 Earnings Call Transcript February 28, 2024 MiMedx Group, Inc. misses on earnings expectations. Reported EPS is $0.04 EPS, expectations were $0.08. MiMedx Group, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and […]
By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT 2023 Financial and Operational Summary MiMedx Group, Inc. (NASDAQ:MDXG) reported full year 2023 revenues of $321.5 million, representing a 20% year over year growth rate, surpassing our $320 million estimate. Pre-tax income was $30.6 million, benefiting from lower expenses on every line. A tax benefit was recognized,